Amarin Corporation plc (NASDAQ:AMRN): According to Jefferies, the FDA Orange Book update during the month contains no decision regarding new chemical entity, or NCE, status exclusivity for Amarin’s Vascepa. Jefferies believes that there will be heightened volatility in Amarin shares because of this, but the firm claims that it continues to be positive on the company’s long-term prospects.
United Parcel Service, Inc. (NYSE:UPS): JPMorgan views risks to the TNT acquisition and the slow economy as being already priced into UPS shares. The firm views the risk/reward on the stock as attractive currently, and it reiterates its Overweight rating on the stock.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO): RBC Capital believes that there is a 70 percent possibility that Aveo’s application for FDA approval of its tivozanib treatment is to be accepted around November 27. The firm predicts that this development has the ability to minimize the risk that faces the company and to cause the stock to increase significantly. It keeps its Outperform rating and an $18 price target on the stock.
Intel Corporation (NASDAQ:INTC): JMP Securities met with the management of Intel’s Client Division, and the firm views the company as being in a good position to take market share in the computing market in Q4 and 2013. The firm expects the company’s Q4 results to be a bit lackluster, but it also believes that the company will rebound over the longer term as its mobile initiatives ramp up. It keeps its Outperform rating on the stock.
Investing Insights: Is Microsoft a Buy After These Events?